S&P 500   4,559.90 (+0.60%)
DOW   35,195.05 (+0.48%)
QQQ   370.12 (+0.99%)
AAPL   167.24 (+0.61%)
MSFT   309.00 (+1.87%)
FB   324.00 (+1.38%)
GOOGL   2,725.06 (+0.84%)
AMZN   3,143.10 (+0.55%)
TSLA   1,014.00 (+1.84%)
NVDA   252.86 (+0.87%)
BABA   135.92 (+6.40%)
NIO   29.47 (+2.93%)
AMD   126.65 (-1.26%)
CGC   7.76 (+1.57%)
MU   90.93 (+1.03%)
GE   100.87 (+0.25%)
T   27.24 (-0.15%)
F   21.76 (-3.07%)
DIS   150.65 (+0.36%)
AMC   18.57 (+1.36%)
PFE   53.50 (-0.07%)
BA   217.53 (+0.21%)
S&P 500   4,559.90 (+0.60%)
DOW   35,195.05 (+0.48%)
QQQ   370.12 (+0.99%)
AAPL   167.24 (+0.61%)
MSFT   309.00 (+1.87%)
FB   324.00 (+1.38%)
GOOGL   2,725.06 (+0.84%)
AMZN   3,143.10 (+0.55%)
TSLA   1,014.00 (+1.84%)
NVDA   252.86 (+0.87%)
BABA   135.92 (+6.40%)
NIO   29.47 (+2.93%)
AMD   126.65 (-1.26%)
CGC   7.76 (+1.57%)
MU   90.93 (+1.03%)
GE   100.87 (+0.25%)
T   27.24 (-0.15%)
F   21.76 (-3.07%)
DIS   150.65 (+0.36%)
AMC   18.57 (+1.36%)
PFE   53.50 (-0.07%)
BA   217.53 (+0.21%)
S&P 500   4,559.90 (+0.60%)
DOW   35,195.05 (+0.48%)
QQQ   370.12 (+0.99%)
AAPL   167.24 (+0.61%)
MSFT   309.00 (+1.87%)
FB   324.00 (+1.38%)
GOOGL   2,725.06 (+0.84%)
AMZN   3,143.10 (+0.55%)
TSLA   1,014.00 (+1.84%)
NVDA   252.86 (+0.87%)
BABA   135.92 (+6.40%)
NIO   29.47 (+2.93%)
AMD   126.65 (-1.26%)
CGC   7.76 (+1.57%)
MU   90.93 (+1.03%)
GE   100.87 (+0.25%)
T   27.24 (-0.15%)
F   21.76 (-3.07%)
DIS   150.65 (+0.36%)
AMC   18.57 (+1.36%)
PFE   53.50 (-0.07%)
BA   217.53 (+0.21%)
S&P 500   4,559.90 (+0.60%)
DOW   35,195.05 (+0.48%)
QQQ   370.12 (+0.99%)
AAPL   167.24 (+0.61%)
MSFT   309.00 (+1.87%)
FB   324.00 (+1.38%)
GOOGL   2,725.06 (+0.84%)
AMZN   3,143.10 (+0.55%)
TSLA   1,014.00 (+1.84%)
NVDA   252.86 (+0.87%)
BABA   135.92 (+6.40%)
NIO   29.47 (+2.93%)
AMD   126.65 (-1.26%)
CGC   7.76 (+1.57%)
MU   90.93 (+1.03%)
GE   100.87 (+0.25%)
T   27.24 (-0.15%)
F   21.76 (-3.07%)
DIS   150.65 (+0.36%)
AMC   18.57 (+1.36%)
PFE   53.50 (-0.07%)
BA   217.53 (+0.21%)
NASDAQ:SRZN

Surrozen Stock Forecast, Price & News

Notice: Trading of Surrozen halted at 09:37 AM EST due to "LULD pause".
$4.07
+0.07 (+1.75%)
(As of 01/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.86
▼
$4.46
50-Day Range
$4.00
▼
$9.92
52-Week Range
$3.86
▼
$14.00
Volume
186,464 shs
Average Volume
113,080 shs
Market Capitalization
$48.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive SRZN News and Ratings via Email

Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter.


Surrozen logo

About Surrozen

Surrozen Inc. is a company pioneering targeted therapeutics which selectively activates the Wnt pathway for tissue repair and regeneration. Surrozen Inc., formerly known as Consonance-HFW Acquisition Corp., is based in SOUTH SAN FRANCISCO, Calif.

Headlines

Analysts Anticipate Surrozen Inc (NASDAQ:SRZN) Will Post Earnings of -$0.46 Per Share
January 19, 2022 |  americanbankingnews.com
Surrozen Inc Shares Near 52-Week Low - Market Mover
January 14, 2022 |  nasdaq.com
Surrozen Inc Shares Fall 1.9% Below Previous 52-Week Low - Market Mover
January 7, 2022 |  nasdaq.com
Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
January 5, 2022 |  finance.yahoo.com
Surrozen Reports Third Quarter 2021 Financial Results
November 15, 2021 |  finance.yahoo.com
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
November 15, 2021 |  finance.yahoo.com
Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference
November 15, 2021 |  finance.yahoo.com
How Many Surrozen, Inc. (NASDAQ:SRZN) Shares Do Institutions Own?
November 11, 2021 |  finance.yahoo.com
Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference
November 5, 2021 |  finance.yahoo.com
Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action
October 7, 2021 |  finance.yahoo.com
Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week
October 5, 2021 |  finance.yahoo.com
Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources
September 23, 2021 |  finance.yahoo.com
SRZN.OQ - Surrozen Inc Profile | Reuters
September 8, 2021 |  reuters.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRZN
Previous Symbol
CUSIP
N/A
CIK
1824893
Web
www.consonancehfw.com
Phone
650-489-9000
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.42 per share
Price / Book
9.69

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.09
Quick Ratio
9.09

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
11,934,000
Free Float
N/A
Market Cap
$48.57 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/20/2022
Next Earnings (Estimated)
2/21/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.83 out of 5 stars

Medical Sector

815th out of 1,415 stocks

Biological Products, Except Diagnostic Industry

132nd out of 206 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Surrozen (NASDAQ:SRZN) Frequently Asked Questions

Is Surrozen a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surrozen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Surrozen stock.
View analyst ratings for Surrozen or view top-rated stocks.

When is Surrozen's next earnings date?

Surrozen is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Surrozen.

How were Surrozen's earnings last quarter?

Surrozen Inc (NASDAQ:SRZN) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.51) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.12.
View Surrozen's earnings history.

What price target have analysts set for SRZN?

3 equities research analysts have issued 1-year target prices for Surrozen's stock. Their forecasts range from $19.00 to $20.00. On average, they anticipate Surrozen's share price to reach $19.50 in the next year. This suggests a possible upside of 379.1% from the stock's current price.
View analysts' price targets for Surrozen or view top-rated stocks among Wall Street analysts.

What is Surrozen's stock symbol?

Surrozen trades on the NASDAQ under the ticker symbol "SRZN."

How do I buy shares of Surrozen?

Shares of SRZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surrozen's stock price today?

One share of SRZN stock can currently be purchased for approximately $4.07.

How much money does Surrozen make?

Surrozen has a market capitalization of $48.57 million.

How many employees does Surrozen have?

Surrozen employs 2,021 workers across the globe.

What is Surrozen's official website?

The official website for Surrozen is www.consonancehfw.com.

Where are Surrozen's headquarters?

Surrozen is headquartered at 1 PALMER SQUARE SUITE 305, PRINCETON NJ, 08540.

How can I contact Surrozen?

Surrozen's mailing address is 1 PALMER SQUARE SUITE 305, PRINCETON NJ, 08540. The company can be reached via phone at 650-489-9000 or via email at [email protected].


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.